← GLP-1 receptor agonists × glycemic control

TrialDiabetologia2007

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

M A Nauck et al.PubMed ↗Publisher ↗

What the trial testedas reported · 501 people · 2007

Range includes no effect

No clear effect on glycemic control

−0.15−0.32 to +0.01

As reported

difference −0.15, 95% CI −0.32 to 0.01

Not counted

Probably lowered glycemic control

−5.40−5.90 to −5.00

As reported

difference −5.4, 95% CI −5.90 to −5.00

Two numbers in the abstract

the abstract, start to end

… aspart -0.89 +/- 0.06%; difference -0.15 [95% CI -0.32 to 0.01]%).

… gained weight [between-group difference -5.4 (95% CI -5.9 to -5.0) kg].

← favours treatmentfavours comparator →
could be chance
Glycemic control
−0.15−0.32 to 0.01
Glycemic control
−5.4−5.90 to −5.00
GLP-1 receptor agonistsInsulinGlycemic control

GLP-1 receptor agonists × glycemic controlhelps?replicated

unlikelylikely
0.900.90 without it

Insulin × glycemic controlhelps?mixed

unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 6

130 papers cite itlatest 60 shown

2007
…
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2022
2023
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 17160407